Genix Receives Approval to Extend Warrants from the TSX Venture Exchange
Genix Receives Approval to Extend Warrants from the TSX Venture Exchange
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2022) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has received approval from the TSX Venture Exchange (the "Exchange") to extend 3,354,945 previously issued and outstanding warrants (the "Warrants") by eighteen (18) months (see July 20, 2022 press release).
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年7月28日)-Genix製藥公司(多倫多證券交易所股票代碼：GEnx)(場外交易市場代碼：GENPF)(以下簡稱“Genix”或“公司”)宣佈，公司已獲得多倫多證券交易所創業板(以下簡稱“交易所”)的批准，將之前發行的和尚未發行的3,354,945份認股權證(以下簡稱“認股權證”)延長十八(18)個月(見2022年7月20日新聞稿)。
In addition, Genix would like to provide a correction to the expiry date on 1,218,333 warrants as published July 20, 2022. The warrants that are set to expire August 13, 2022 and will be extended 18 months to February 13, 2024 not February 13, 2023 as was written in the press release.
此外，Genix希望對2022年7月20日公佈的1,218,333份認股權證的到期日進行更正。這些認股權證將於2022年8月13日到期，並將延長18個月至2024年2月13日，而不是新聞稿中寫的2023年2月13日。
About Genix
Genix Pharmaceuticals Corporation is a novel and generic ophthalmic drugs company. The Company is focused on the research, development, manufacture, licensing and sales of novel and innovative healthcare products. In particular, these products include evidence-based, proprietary over-the-counter ("OTC") nutraceuticals, and other single molecule generic drugs that have been shown to deliver consistent and verifiable results in various therapeutic areas.
關於Genix
Genix製藥公司是一家新型的仿製藥眼科藥物公司。該公司專注於新型和創新保健產品的研究、開發、製造、許可和銷售。特別是，這些產品包括循證的、專有的非處方藥(“OTC”)營養食品，以及其他單分子仿製藥，已被證明在不同的治療領域提供一致和可驗證的結果。
The Company will market and sell its portfolio of novel and generic ophthalmic drugs in Canada and globally and its nutraceutical products in North America and other select countries. Genix continues to conduct its scientific R&D of new, innovative products to support the health needs of mainstream consumers.
該公司將在加拿大和全球營銷和銷售其新型和非專利眼科藥物組合，並在北美和其他選定的國家和地區銷售其營養食品產品。Genix繼續對新的、創新的產品進行科學研發，以支持主流消費者的健康需求。
On Behalf of the Board of Directors,
我謹代表董事會：
Mr. Mahmoud Aziz, President, Director
Genix Pharmaceuticals Corporation
董事馬哈茂德·阿齊茲先生，總裁
Genix製藥公司
For more information regarding Genix Pharmaceuticals Corporation, please contact:
欲瞭解有關Genix製藥公司的更多信息，請聯繫：
Kevin Bottomley, Director
Tel: +1.604.609.6199kbottomley@genixpharm.com
凱文·博託姆利，董事
電話：+1.604.609.6199kbottomley@genixPharm.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward‐looking statements". Forward‐looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward‐looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward‐looking statements.
本公告中包含的聲明，包括與我們的計劃、意圖和預期有關的聲明，並非歷史性的聲明，本聲明旨在並在此將其識別為“前瞻性聲明”。前瞻性陳述可以用包括“預期”、“相信”、“打算”、“估計”、“預期”和類似表述的詞語來識別。公司提醒讀者，前瞻性陳述，包括但不限於與公司未來運營和業務前景有關的陳述，會受到某些風險和不確定因素的影響，這些風險和不確定因素可能會導致實際結果與前瞻性陳述中所述的大不相同。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。